Den anden undersøgelse så på, hvorvidt Aprovel forlænger den tid, der går, inden patienterne oplever en fordobling af deres blodkreatininniveauer (en markør for nyresygdom), får behov for en nyretransplantation eller dialyse, eller inden patienterne dør.
The second study looked at whether Aprovel increased the time taken until the patients ’ blood creatinine levels had doubled (a marker of kidney disease), until they needed a kidney transplant or dialysis, or until they died.